Febit’s new patented method is known as hybselect, targeted sequencing or sequence capture. Using this technique, researchers are able to isolate genes or genomic regions of interest from a complex DNA sample prior to sequencing.
Febit’s microfluidic microarray-based method forms the basis of a novel technology that enables the expanded use of next-generation sequencers in genomic research. Further investigation of the human genome by resequencing will particularly benefit from the new method: febit uses its microfluidic biochip system for sequence-based selective isolation of nucleic acids from genomic samples.